Doximity
DOCS
$26.73
+4.45%
Doximity, Inc. operates a leading digital platform for healthcare professionals in the United States, connecting physicians with colleagues, medical news, and tools for telehealth, documentation, and career management. The company monetizes its network through marketing, hiring, and workflow solutions sold to pharmaceutical companies and health systems, positioning itself as a dominant niche player in the healthcare information services industry. The current investor narrative centers on the company's AI-driven growth initiatives, which have recently boosted revenue and sparked a sharp post-earnings rally, while also facing scrutiny over decelerating growth and a significant drawdown from its 2021 highs. Debates revolve around whether Doximity can sustain its AI momentum and expand its total addressable market despite a challenging macro environment and competitive pressures.…
DOCS
Doximity
$26.73
Related headlines
Investment Opinion: Should I buy DOCS Today?
We rate Doximity a Hold. The stock offers a compelling risk/reward at current levels, with a forward PE of 17.3x and analyst average target of $29.78 implying 11.4% upside. However, the decelerating growth and high uncertainty warrant caution.
Sign up to view all
DOCS 12-Month Price Forecast
The AI-driven growth narrative is compelling, supported by recent earnings and a reasonable valuation. However, the medium confidence reflects the uncertainty in sustaining growth. If AI continues to deliver, the stock could re-rate higher; if not, the downside is significant. We would upgrade to high confidence if revenue growth reaccelerates above 15% and downgrade if growth falls below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Doximity's 12-month outlook, with a consensus price target around $29.78 and implied upside of +11.4% versus the current price.
Average Target
$29.78
0 analysts
Implied Upside
+11.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$18 - $47
Analyst target range
The target price range is $18.00 to $47.00, with a wide spread of $29.00, indicating high uncertainty about the stock's future performance. The low target of $18.00 implies a downside of -32.7% from the current price, while the high target of $47.00 implies an upside of 75.8%. The high target likely assumes that the company's AI initiatives will drive accelerating growth and margin expansion, while the low target may price in continued deceleration and competitive pressures. Recent institutional ratings show a mix of actions, with some firms maintaining Overweight ratings and others at Neutral, but no recent downgrades to Underweight, suggesting that sentiment is cautiously optimistic. The wide target spread reflects the market's uncertainty about the sustainability of Doximity's growth and the impact of AI on its business model.
Drowning in data?
Find the real signal!
Bulls vs Bears: DOCS Investment Factors
Doximity presents a mixed picture: strong profitability, a dominant niche, and a reasonable valuation are offset by decelerating growth and a prolonged downtrend. The bull case hinges on AI-driven reacceleration, which recent earnings support, but the bear case warns of continued deceleration and competitive threats. Currently, the evidence slightly favors the bulls given the recent earnings beat and AI momentum, but the key tension is whether AI can sustain growth above 10% YoY. If AI monetization proves durable, the stock has significant upside; if not, the valuation could compress further.
Bullish
- AI-driven growth reaccelerating: Recent earnings showed a 9.8% YoY revenue increase to $185.1M, with management citing AI investments delivering 10x unit economics. This sparked a 30% post-earnings surge, indicating the market sees AI as a transformative growth driver.
- Exceptional profitability and cash flow: Gross margin stands at 89.1%, operating margin at 33.3%, and net margin at 30.4%. Free cash flow TTM is $311.5M, representing a strong cash generation capability that supports reinvestment and shareholder returns.
- Undemanding valuation with forward PE of 17.3x: The forward PE of 17.3x is below the trailing PE of 22.2x, implying expected earnings growth of ~28%. This is modest for a high-margin SaaS company, offering a reasonable entry point if growth sustains.
- Dominant niche in healthcare professional network: Doximity connects over 80% of U.S. physicians, creating a powerful network effect. This entrenched position provides a competitive moat and recurring subscription revenue (94.8% of total revenue).
Bearish
- Sharp growth deceleration from prior years: Revenue growth slowed to 9.8% YoY in Q3 FY2026, down from 23% in the prior year. This deceleration raises concerns about market saturation and the sustainability of the company's growth narrative.
- Significant long-term downtrend: The stock is down 60.9% over the past year and trades 65% below its 52-week high of $76.51. This persistent decline reflects a loss of investor confidence and a de-rating from peak valuation multiples.
- High uncertainty reflected in wide analyst targets: Analyst targets range from $18 to $47, a spread of $29, indicating low conviction. The low target implies a 32.7% downside from the current price, highlighting the risk of further declines.
- Dependence on AI narrative for valuation support: The recent rally is driven by AI optimism, but if AI monetization fails to meet expectations, the stock could re-rate downward. The forward PE already prices in significant earnings growth, leaving little room for disappointment.
DOCS Technical Analysis
Doximity's stock is in a pronounced long-term downtrend, with a 1-year price change of -60.9%, and currently trades at $26.73, which is only 35% of its 52-week high of $76.51 and 156% above its 52-week low of $17.15. The stock's position near the lower end of its 52-week range suggests a potential value opportunity, but the persistent downtrend indicates that selling pressure has dominated, and the stock has yet to establish a clear bottom. The 52-week low of $17.15 was set in May 2026, and the stock has since recovered, but it remains well below its historical highs, reflecting a significant loss of investor confidence.
Beta
1.21
1.21x market volatility
Max Drawdown
-76.0%
Largest decline past year
52-Week Range
$17-$77
Price range past year
Annual Return
-60.9%
Cumulative gain past year
| Period | DOCS Return | S&P 500 |
|---|---|---|
| 1m | +23.6% | +3.0% |
| 3m | +24.9% | +1.4% |
| 6m | +9.0% | +13.1% |
| 1y | -60.9% | +19.3% |
| ytd | -38.3% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOCS Fundamental Analysis
Doximity's revenue growth has been robust, with the most recent quarter (Q3 FY2026, ended December 31, 2025) reporting revenue of $185.1 million, a 9.8% year-over-year increase. This growth is a deceleration from the prior year's pace, as the company's revenue for the same quarter in 2024 was $168.6 million, representing a 9.8% YoY growth, down from the 23% growth seen in the prior year. The company's revenue segments show that subscription revenue of $175.4 million dominates, while service and other revenue contributed $9.7 million, indicating a subscription-based model with high recurring revenue. The growth trajectory, while slowing, remains positive, and the company's AI investments are cited as a key driver for future expansion, as highlighted in recent news.
Quarterly Revenue
$185053000.0B
2025-12
Revenue YoY Growth
+9.8%
YoY Comparison
Gross Margin
89.9%
Latest Quarter
Free Cash Flow
$311547000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOCS Overvalued?
Given that Doximity is profitable, the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 22.2x, while the forward PE is 17.3x, indicating that the market expects earnings growth of approximately 28% over the next year. This gap between trailing and forward PE suggests that the market is pricing in a significant acceleration in earnings, which aligns with the company's AI-driven growth narrative. The forward PE of 17.3x is below the trailing PE, implying that the market expects earnings to grow, but the absolute level is moderate for a software company, reflecting the stock's de-rating from its historical highs.
PE
22.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 27x~104x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include decelerating revenue growth, which fell to 9.8% YoY in Q3 FY2026 from 23% a year earlier, potentially indicating market saturation. While the company is profitable with a net margin of 30.4%, its reliance on subscription revenue (94.8% of total) creates concentration risk if customer churn increases. The balance sheet is strong with minimal debt (D/E 0.011) and ample liquidity (current ratio 6.09), but the high valuation multiples (PS 6.76, EV/EBITDA 15.69) leave little margin for error if growth disappoints.
